Cargando…

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong

Human papillomavirus (HPV) can cause several diseases, including cancers, in both sexes. In January 2020, the Hong Kong government launched a school-based vaccination program for girls 10–12 years of age with the 9-valent HPV (9vHPV) vaccine for the prevention of HPV-related diseases; however, boys...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Tak Hong, Cheng, Sally Shuk Yee, Hsu, Danny, Wing-Lei Wong, Queenie, Pavelyev, Andrew, Sukarom, Isaya, Saxena, Kunal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
HPV
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208209/
https://www.ncbi.nlm.nih.gov/pubmed/37183965
http://dx.doi.org/10.1080/21645515.2023.2184605
_version_ 1785046623910363136
author Cheung, Tak Hong
Cheng, Sally Shuk Yee
Hsu, Danny
Wing-Lei Wong, Queenie
Pavelyev, Andrew
Sukarom, Isaya
Saxena, Kunal
author_facet Cheung, Tak Hong
Cheng, Sally Shuk Yee
Hsu, Danny
Wing-Lei Wong, Queenie
Pavelyev, Andrew
Sukarom, Isaya
Saxena, Kunal
author_sort Cheung, Tak Hong
collection PubMed
description Human papillomavirus (HPV) can cause several diseases, including cancers, in both sexes. In January 2020, the Hong Kong government launched a school-based vaccination program for girls 10–12 years of age with the 9-valent HPV (9vHPV) vaccine for the prevention of HPV-related diseases; however, boys were not included. The current study estimated the potential health and economic impact of a routine gender-neutral vaccination (GNV) approach compared with the current female-only vaccination (FOV) strategy. We used a dynamic transmission model, adapted to Hong Kong. The model estimates changes in HPV-related disease incidence and mortality, treatment costs (in 2019 Hong Kong dollars), quality-adjusted life years (QALY), and incremental cost-effectiveness ratios (ICERs) over a 100-year time horizon. The base case analysis compared FOV with the 9vHPV vaccine with routine GNV (coverage rate 70%) for the prevention of HPV-related diseases. Compared with a FOV approach, routine GNV with the 9vHPV vaccine is predicted to provide greater reductions in cumulative HPV-related disease incidence and mortality, as well as lower HPV-related treatment costs. In the base case analysis, the ICER was $248,354 per QALY for routine GNV. As compared with FOV, routine GNV fell below the cost-effectiveness ceiling of $382,046/year for Hong Kong. These results highlight the potential value of a routine GNV program with the 9vHPV vaccine among 12-year-olds in Hong Kong to reduce the public health and economic burden of HPV-related diseases.
format Online
Article
Text
id pubmed-10208209
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-102082092023-05-25 Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong Cheung, Tak Hong Cheng, Sally Shuk Yee Hsu, Danny Wing-Lei Wong, Queenie Pavelyev, Andrew Sukarom, Isaya Saxena, Kunal Hum Vaccin Immunother HPV Human papillomavirus (HPV) can cause several diseases, including cancers, in both sexes. In January 2020, the Hong Kong government launched a school-based vaccination program for girls 10–12 years of age with the 9-valent HPV (9vHPV) vaccine for the prevention of HPV-related diseases; however, boys were not included. The current study estimated the potential health and economic impact of a routine gender-neutral vaccination (GNV) approach compared with the current female-only vaccination (FOV) strategy. We used a dynamic transmission model, adapted to Hong Kong. The model estimates changes in HPV-related disease incidence and mortality, treatment costs (in 2019 Hong Kong dollars), quality-adjusted life years (QALY), and incremental cost-effectiveness ratios (ICERs) over a 100-year time horizon. The base case analysis compared FOV with the 9vHPV vaccine with routine GNV (coverage rate 70%) for the prevention of HPV-related diseases. Compared with a FOV approach, routine GNV with the 9vHPV vaccine is predicted to provide greater reductions in cumulative HPV-related disease incidence and mortality, as well as lower HPV-related treatment costs. In the base case analysis, the ICER was $248,354 per QALY for routine GNV. As compared with FOV, routine GNV fell below the cost-effectiveness ceiling of $382,046/year for Hong Kong. These results highlight the potential value of a routine GNV program with the 9vHPV vaccine among 12-year-olds in Hong Kong to reduce the public health and economic burden of HPV-related diseases. Taylor & Francis 2023-05-15 /pmc/articles/PMC10208209/ /pubmed/37183965 http://dx.doi.org/10.1080/21645515.2023.2184605 Text en © 2023 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle HPV
Cheung, Tak Hong
Cheng, Sally Shuk Yee
Hsu, Danny
Wing-Lei Wong, Queenie
Pavelyev, Andrew
Sukarom, Isaya
Saxena, Kunal
Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
title Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
title_full Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
title_fullStr Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
title_full_unstemmed Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
title_short Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
title_sort health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent hpv vaccine in hong kong
topic HPV
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208209/
https://www.ncbi.nlm.nih.gov/pubmed/37183965
http://dx.doi.org/10.1080/21645515.2023.2184605
work_keys_str_mv AT cheungtakhong healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong
AT chengsallyshukyee healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong
AT hsudanny healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong
AT wingleiwongqueenie healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong
AT pavelyevandrew healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong
AT sukaromisaya healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong
AT saxenakunal healthimpactandcosteffectivenessofimplementinggenderneutralvaccinationwiththe9valenthpvvaccineinhongkong